Evidence map›Paper›PMID 21356241›Full record

ReviewPharmacology & therapeutics2011

Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.

Tina K Machu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacology & therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 4 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Isopropyl alcohol inhalation versus 5-HTEuropean journal of clinical pharmacology · 2023
    Pooled it
  3. 5-HTCurrent neuropharmacology · 2021
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Quetiapine competitively inhibits 5-HTThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Article
  18. Fibromyalgia: Chronic Pain Due to a Blood Dysfunction?International journal of molecular sciences · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Tina K MachuDept. of Medical Education and Dept. of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd. Fort Worth, TX 76107-2699, USA. tina.machu@unthsc.edu
University of North Texas · US

Funding

ALCOHOL MODULATORY SITES IN THE 5HT3A RECEPTORR01AA012643 · NIAAA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI MACHU, TINA K · 2001 to 2005
$1.4M
Ligand Binding Domains in the 5-HT3 ReceptorR01NS043438 · NINDS · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI MACHU, TINA K · 2003 to 2006
$980k
NIAAA NIH HHS R01 AA012643NINDS NIH HHS R01 NS043438
6 · The paper itself

Abstract

The 5-Hydroxytryptamine3 (5-HT3) receptor is a member of the cys-loop family of ligand gated ion channels, of which the nicotinic acetylcholine receptor is the prototype. All other 5-HT receptors identified to date are metabotropic receptors. The 5-HT3 receptor is present in the central and peripheral nervous systems, as well as a number of non-nervous tissues. As an ion channel that is permeable to the cations, Na(+), K(+), and Ca(2+), the 5-HT3 receptor mediates fast depolarizing responses in pre- and post-synaptic neurons. As such, 5-HT3 receptor antagonists that are used clinically block afferent and efferent synaptic transmission. The most well established physiological roles of the 5-HT3 receptor are to coordinate emesis and regulate gastrointestinal motility. Currently marketed 5-HT3 receptor antagonists are indicated for the treatment of chemotherapy, radiation, and anesthesia-induced nausea and vomiting, as well as irritable bowel syndrome. Other therapeutic uses that have been explored include pain and drug addiction. The 5-HT3 receptor is one of a number of receptors that play a role in mediating nausea and vomiting, and as such, 5-HT3 receptor antagonists demonstrate the greatest anti-emetic efficacy when administered in combination with other drug classes.

Indexed as

AnimalsForecastingGastrointestinal MotilityHumansIrritable Bowel SyndromeNauseaReceptors, Serotonin, 5-HT3Serotonin 5-HT3 Receptor AntagonistsVomitingReceptors, Serotonin, 5-HT3Serotonin 5-HT3 Receptor Antagonists

Identifiers

PMID21356241
PMCPMC3103470
OpenAlexW2049652736

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.